Sophia Genetics backs FY25 revenue view $72M-$76M, consensus $74.2M

Backs FY25 adjusted EBITDA loss $35M-$39M. Camblong added, “In addition to the strong performance, we also secured impressive new business wins in Q2 to fuel future growth. We signed 35 new core genomics customers in Q2 by capitalizing on robust Clinical demand across geographies and innovative new applications. We also announced the largest contract in company history with the signing of a multi-year AI breast cancer partnership with AstraZeneca, which demonstrates the significant value of the SOPHiA GENETICS’s (SOPH) network and AI capabilities to BioPharma.”